Eli Lilly and Company’s Stock Price Plummets to $741.41, Experiencing a Sharp 7.03% Drop

Eli Lilly and Company (LLY)

741.41 USD -56.06 (-7.03%) Volume: 8.92M

Eli Lilly and Company’s stock price is currently at 741.41 USD, experiencing a decrease of -7.03% this trading session with a trading volume of 8.92M, indicating a substantial market activity. Despite a year-to-date percentage change of -4.15%, LLY continues to be a significant player in the pharmaceutical industry.

Latest developments on Eli Lilly and Company

Eli Lilly & Company recently provided an update on its 2024 revenue guidance and announced its 2025 revenue guidance. The pharmaceutical giant’s stock price has been on a rollercoaster ride due to various factors, including disappointing sales of Mounjaro and Zepbound, leading to a drop in stock value. The company’s CEO is optimistic about the approval of a new weight loss pill next year. Additionally, Eli Lilly made headlines for acquiring Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program and suing two medical spas over copycat weight-loss drugs. Despite the challenges, the company remains focused on innovation and growth, with expectations for a bright 2025. Investors are closely watching Eli Lilly’s stock movements as it navigates through the changing pharmaceutical landscape.

A look at Eli Lilly and Company Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Eli Lilly & has a positive long-term outlook. With high scores in Growth and Momentum, the company is positioned well for future success in the pharmaceutical industry. While Value and Resilience scores are not as high, the strong performance in Growth and Momentum factors indicate potential for continued growth and market success.

Eli Lilly & Company, a pharmaceutical giant, has received a favorable overall outlook based on the Smartkarma Smart Scores. With solid scores in Dividend and Growth, the company shows promise for investors looking for stability and potential for growth. While Value and Resilience scores are not as high, the strong Momentum score suggests that Eli Lilly & is on a path towards continued success in the pharmaceutical market.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma